head and neck cancer

2022 ASCO Annual Meeting; #ASCO22
August 25, 2022 · Brielle Gregory Collins, ASCO staff

2022 ASCO Annual Meeting Research Round Up: New Research in Head and Neck Cancer, Brain Tumors, and Health Equity

In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2022 ASCO Annual Meeting in head and neck cancer, brain tumors, and health equity. Read More >>
ASCO ® Plenary Series
April 18, 2022 · Greg Guthrie, ASCO staff

Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO Plenary Series

Read research from the April 2022 session of the ASCO Plenary Series, which highlights a clinical trial that studied a medication called tislelizumab combined with chemotherapy to treat recurrent or metastatic nasopharyngeal cancer. Read More >>
April 14, 2022 · Perrin Romine, MD, and Kedar Kirtane, MD

Getting Help for Sexual Health Problems When You Have Head and Neck Cancer: An Expert Q&A

Dr. Kedar Kirtane and Dr. Perrin Romine discuss the common sexual health concerns people with head and neck cancer have and how to get help with these concerns during and after cancer. Read More >>
March 31, 2022 · Brielle Gregory Collins, ASCO staff

Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and Neck Cancers: 2022 Multidisciplinary Head and Neck Cancers Symposium

In this podcast, Dr. Kedar Kirtane discusses research from the 2022 Multidisciplinary Head and Neck Cancers Symposium, including discussions around cancer disparities in head and neck cancer, treatment for HPV-positive oropharyngeal cancer, and strategies for treating HPV-related head and neck cancers. Read More >>
2021 ASCO Annual Meeting; #ASCO21
June 3, 2021 · ASCO Staff

2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Kidney Cancer, and Nasopharyngeal Cancer

The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer. Read More >>

Pages